Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable JAK Inhibitor (Pan) Debio 0617B Preclinical - Patient cell culture Actionable In a preclinical study, Debio 0617B inhibited survival of a variety of patient-derived tumor cells in culture (PMID: 27439479). 27439479
Unknown unknown Advanced Solid Tumor not applicable JAK3 Inhibitor AT9283 Phase I Actionable In a Phase I clinical trial, AT9283 demonstrated safety and efficacy in patients with advanced solid tumors (PMID: 22015452). 22015452
Unknown unknown acute leukemia no benefit JAK3 Inhibitor AT9283 Phase Ib/II Actionable In a Phase I/II trial, AT9283 demonstrated tolerable toxicity but no clinical response in children with acute leukemia, although the trial failed to identify its primary endpoints due to poor recruitment and early termination (PMID: 27905678). 27905678
Unknown unknown diffuse large B-cell lymphoma not applicable JAK3 Inhibitor - ATP competitive Cerdulatinib Preclinical Actionable In a preclinical study, treatment with Cerdulatinib (PRT062070) resulted in decreased viability and increased apoptosis of diffuse large B-cell lymphoma cells in culture (PMID: 25253883). 25253883
Unknown unknown Burkitt lymphoma not applicable JAK3 Inhibitor - ATP competitive Cerdulatinib Preclinical Actionable In a preclinical study, treatment with Cerdulatinib (PRT062070) resulted in decreased viability and increased apoptosis of Burkitt lymphoma cells in culture (PMID: 25253883). 25253883
Unknown unknown chronic lymphocytic leukemia not applicable JAK3 Inhibitor - ATP competitive Cerdulatinib Preclinical - Patient cell culture Actionable In a preclinical study, Cerdulatinib (PRT062070) decreased BCR downstream signaling and chemokine secretion, and reduced viability of patient-derived chronic lymphocytic leukemia (CLL) cells in culture (PMID: 27697994). 27697994
Unknown unknown chronic lymphocytic leukemia not applicable JAK3 Inhibitor - ATP competitive Cerdulatinib + Venetoclax Preclinical - Patient cell culture Actionable In a preclinical study, the combination of Cerdulatinib (PRT062070) and Venclexta (venetoclax) worked synergistically to induce apoptosis of patient-derived chronic lymphocytic leukemia cells in culture, and resulted in decreased cell viability compared to either drug as a single agent (PMID: 27697994). 27697994
Clinical Trial Phase Therapies Title Recruitment Status